Media stories about Taro Pharmaceutical Industries (NYSE:TARO) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Taro Pharmaceutical Industries earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the company an impact score of 44.3538430808758 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of NYSE TARO opened at $98.25 on Friday. The firm has a market capitalization of $3,990.15, a PE ratio of 8.88 and a beta of 0.62. Taro Pharmaceutical Industries has a fifty-two week low of $93.01 and a fifty-two week high of $128.46.
Taro Pharmaceutical Industries (NYSE:TARO) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $1.37 earnings per share (EPS) for the quarter. The company had revenue of $155.46 million during the quarter. Taro Pharmaceutical Industries had a return on equity of 11.35% and a net margin of 30.43%. analysts anticipate that Taro Pharmaceutical Industries will post 5.28 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Taro Pharmaceutical Industries (TARO) Receiving Somewhat Favorable News Coverage, Analysis Finds” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3336615/taro-pharmaceutical-industries-taro-receiving-somewhat-favorable-news-coverage-analysis-finds.html.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.